Comparison of the effect of teicoplanin and vancomycin on experimental methicillin-resistant staphylococcus aureus keratitis

被引:6
|
作者
Ucgul, Ahmet Yucel [1 ]
Behcet, Mustafa [2 ]
机构
[1] Abant Izzet Baysal Univ, Training & Res Hosp, Dept Ophthalmol, Kilicarslan Mah 144,Sk 7-6 Merkez, Bolu, Turkey
[2] Abant Izzet Baysal Univ, Training & Res Hosp, Dept Med Microbiol, Bolu, Turkey
关键词
Keratitis; Methicillin-resistant staphylococcus aureus; Teicoplanin; Vancomycin;
D O I
10.1007/s10792-021-01696-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate the early efficacy and safety of intrastromal injection of teicoplanin as the alternative treatment for the methicillin-resistant Staphylococcus aureus (MRSA) keratitis by comparing it with vancomycin. Materials and methods Twenty-four eyes of 24 New Zealand white rabbits were included in the study. MRSA keratitis was induced in the right eye of each rabbit by injecting 0.1 mL MRSA suspension containing 1000 colony-forming units (CFU) intrastromally to the central cornea. The rabbits were divided into three treatment groups 24 h after the inoculation of MRSA. Eight rabbits received intrastromal teicoplanin therapy, eight received intrastromal vancomycin therapy, and eight received balanced salt solution and served as the control group. Nine hours after the treatment, all rabbits were sacrificed and corneal tissues were collected for microbiological analysis. We also examined and scored all the rabbits clinically before and after the treatment. Results The control group scored higher with regard to conjunctival injection, iritis, fibrin, hypopyon, epithelial erosion, and corneal infiltrate than the vancomycin and teicoplanin groups (p = 0.031, 0.010, < 0.001, 0.029, 0.009, and < 0.001, respectively). Chemosis and corneal oedema were similar in all groups (p = 0.731 and 0.075, respectively). The severity of all clinical parameters was similar in both the vancomycin and teicoplanin groups after the treatment. The bacterial load was the highest (7.83 +/- 0.71 log(10) CFU/g) in the control group. The eyes treated with vancomycin and teicoplanin had similar bacterial loads (6.40 +/- 0.69 vs. 6.31 +/- 0.75 log(10) CFU/g, p = 0.809). Conclusion The efficiency of teicoplanin seems to be comparable to that of vancomycin when administered intrastromally in the early treatment of MRSA keratitis. The former may be preferred in the treatment of selected cases with vancomycin hypersensitivity or resistance.
引用
收藏
页码:1395 / 1402
页数:8
相关论文
共 50 条
  • [21] TEICOPLANIN COMPARED WITH VANCOMYCIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS INFECTIONS - PRELIMINARY-RESULTS
    VANLAETHEM, Y
    HERMANS, P
    DEWIT, S
    GOOSENS, H
    CLUMECK, N
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 21 : 81 - 87
  • [22] Comparative effectiveness of teicoplanin versus vancomycin in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia
    Hsieh, Hsing-Chun
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 96 - 96
  • [23] Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci
    Jumaa, PA
    Hateley, PM
    Tabaqchali, S
    LANCET, 1997, 350 (9079): : 738 - 739
  • [24] Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci
    Nelson, RRS
    LANCET, 1997, 350 (9087): : 1327 - 1327
  • [25] Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections
    Wu, Wei
    Liu, Min
    Geng, Jia-Jing
    Wang, Mei
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (34) : 10549 - 10556
  • [26] Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections
    Wei Wu
    Min Liu
    Jia-Jing Geng
    Mei Wang
    World Journal of Clinical Cases, 2021, 9 (34) : 10549 - 10556
  • [27] Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus
    Fitch, L
    Johnson, AP
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (05) : 578 - 578
  • [28] Vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus, Taiwan
    Wang, JL
    Tseng, SP
    Hsueh, PR
    Hiramatsu, K
    EMERGING INFECTIOUS DISEASES, 2004, 10 (09) : 1702 - 1704
  • [29] Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
    Holmes, Natasha E.
    Tong, Steven Y. C.
    Davis, Joshua S.
    van Hal, Sebastiaan J.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 36 (01) : 17 - 30
  • [30] VANCOMYCIN THERAPY FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    SORRELL, TC
    PACKHAM, DR
    SHANKER, S
    FOLDES, M
    MUNRO, R
    ANNALS OF INTERNAL MEDICINE, 1982, 97 (03) : 344 - 350